Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Clinical trial NCT06006013 · RECRUITING

Trial details

NCT number: NCT06006013
Sponsor: Emory University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Adrenal Cortex Carcinoma Adrenal Cortical Carcinoma Stage III Adrenal Cortex Carcinoma Stage IV Adrenal Cortex Carcinoma AJCC v8 Unresectable Adrenal Cortex Carcinoma

Start date: 2025-01-15
Primary completion: 2027-12-16
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.